.STUDY FEATURE.06 August 2024.
A huge randomized measured test with cisgender women highlights the challenges of adherence to an everyday oral preexposure prevention regiment and displays that twice-yearly treatment of lenacapavir can preserve effective HIV prevention levels over 6 months.